RDT is pleased to announce that its latest product Tempus Pro has been CE Marked and 510k cleared to market by the US Food and Drug Administration. All medical products must achieve these clearances before they can be marketed in the US and much of the rest of the world.
Tempus Pro is a new concept in vital signs monitoring that places the needs of the military medic and pre-hospital care professional at the heart of its design. Ground breaking in functionality, the monitor is light enough to carry to the patient, small enough to hold in one hand and rugged enough to deploy in any situation.
Tempus Pro provides all the integrated features and capabilities expected in a market-leading vital signs monitor with unmatched durability, daylight readable display, long battery life, intuitive interface and a glove-friendly touch screen that enables ease of use for both advanced and basic life support paramedics and emergency practitioners.
The additional ability to easily document and share all patient data electronically ensures that all care providers have accurate information on patient injuries, therapies, trending vital signs, drugs and fluids that can be handed over, or sent ahead via ReachBakTM, ahead of the patient arriving at hospital or next level of care.
The platform is designed to be scalable to accommodate immediate and evolving needs and budgets, with the ability to add advanced capabilities post purchase. This will enable users to perform a new range of diagnostic processes on patients using the same battery and display already being carried. This flexibility and scalability enables users to leverage the most from their pre-hospital/transport monitor investment.
RDT’s Programme & Regulatory Affairs Director, Chris Hannan, comments “We are proud that Tempus Pro has been CE Marked and cleared to market by the FDA. RDT is excited to offer a 21st century approach to vital signs monitoring with solutions that meet the needs as described by the modern war fighter and the pre-hospital care professional. I believe it represents a new benchmark in vital signs monitoring and feel this is validated by the overwhelming commercial response we have had already.”